Greg Harrison
Stock Analyst at B of A Securities
(4.62)
# 196
Out of 5,126 analysts
102
Total ratings
59.49%
Success rate
26.51%
Average return
Main Sectors:
Stocks Rated by Greg Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AGIO Agios Pharmaceuticals | Maintains: Buy | $32 → $34 | $26.53 | +28.16% | 9 | Dec 24, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $36 → $30 | $12.28 | +144.30% | 3 | Oct 27, 2025 | |
| UTHR United Therapeutics | Maintains: Neutral | $314 → $463 | $485.36 | -4.61% | 5 | Sep 2, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $38 → $43 | $29.77 | +44.44% | 2 | Aug 28, 2025 | |
| TVTX Travere Therapeutics | Maintains: Sector Outperform | $30 → $31 | $29.71 | +4.34% | 6 | Aug 7, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Sector Outperform | $22 → $20 | $9.16 | +118.34% | 2 | Aug 6, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Sector Outperform | $55 → $57 | $68.05 | -16.24% | 7 | Aug 6, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $442 → $438 | $477.92 | -8.35% | 7 | Aug 5, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Sector Outperform | $342 → $450 | $328.16 | +37.13% | 6 | Aug 1, 2025 | |
| GOSS Gossamer Bio | Initiates: Sector Outperform | $11 | $2.26 | +386.73% | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $32 → $35 | $7.57 | +362.35% | 2 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $65 → $55 | $43.50 | +26.44% | 3 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $51 → $19 | $3.16 | +501.27% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $36 → $37 | $43.04 | -14.03% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $41 → $26 | $17.60 | +47.73% | 6 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $28 → $20 | $23.47 | -14.78% | 4 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $4 → $1.5 | $1.53 | -1.96% | 3 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $40 | $26.52 | +50.83% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $73 → $75 | $79.72 | -5.92% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $18 | $13.30 | +35.34% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $32.40 | -62.96% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $5 → $1.5 | $0.40 | +275.00% | 1 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $15 | $1.82 | +724.18% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 | $11.23 | -73.29% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $0.93 | +7,424.45% | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $54 | $13.22 | +308.47% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $270 → $90 | $36.81 | +144.50% | 5 | Mar 14, 2022 |
Agios Pharmaceuticals
Dec 24, 2025
Maintains: Buy
Price Target: $32 → $34
Current: $26.53
Upside: +28.16%
Intellia Therapeutics
Oct 27, 2025
Maintains: Buy
Price Target: $36 → $30
Current: $12.28
Upside: +144.30%
United Therapeutics
Sep 2, 2025
Maintains: Neutral
Price Target: $314 → $463
Current: $485.36
Upside: -4.61%
Mineralys Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $38 → $43
Current: $29.77
Upside: +44.44%
Travere Therapeutics
Aug 7, 2025
Maintains: Sector Outperform
Price Target: $30 → $31
Current: $29.71
Upside: +4.34%
Ocular Therapeutix
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $22 → $20
Current: $9.16
Upside: +118.34%
BridgeBio Pharma
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $55 → $57
Current: $68.05
Upside: -16.24%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Sector Perform
Price Target: $442 → $438
Current: $477.92
Upside: -8.35%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Sector Outperform
Price Target: $342 → $450
Current: $328.16
Upside: +37.13%
Gossamer Bio
Jul 14, 2025
Initiates: Sector Outperform
Price Target: $11
Current: $2.26
Upside: +386.73%
Jul 2, 2025
Maintains: Sector Outperform
Price Target: $32 → $35
Current: $7.57
Upside: +362.35%
Jun 2, 2025
Maintains: Sector Outperform
Price Target: $65 → $55
Current: $43.50
Upside: +26.44%
May 28, 2025
Maintains: Sector Outperform
Price Target: $51 → $19
Current: $3.16
Upside: +501.27%
May 28, 2025
Maintains: Sector Outperform
Price Target: $36 → $37
Current: $43.04
Upside: -14.03%
May 12, 2025
Maintains: Sector Outperform
Price Target: $41 → $26
Current: $17.60
Upside: +47.73%
May 8, 2025
Maintains: Sector Perform
Price Target: $28 → $20
Current: $23.47
Upside: -14.78%
May 8, 2025
Downgrades: Sector Perform
Price Target: $4 → $1.5
Current: $1.53
Upside: -1.96%
Mar 10, 2025
Upgrades: Sector Outperform
Price Target: $40
Current: $26.52
Upside: +50.83%
Mar 3, 2025
Maintains: Sector Outperform
Price Target: $73 → $75
Current: $79.72
Upside: -5.92%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $18
Current: $13.30
Upside: +35.34%
May 1, 2023
Upgrades: Neutral
Price Target: $9 → $12
Current: $32.40
Upside: -62.96%
Apr 28, 2023
Downgrades: Underperform
Price Target: $5 → $1.5
Current: $0.40
Upside: +275.00%
Nov 18, 2022
Maintains: Neutral
Price Target: $18 → $15
Current: $1.82
Upside: +724.18%
Nov 8, 2022
Downgrades: Underperform
Price Target: $3
Current: $11.23
Upside: -73.29%
Sep 29, 2022
Initiates: Buy
Price Target: $70
Current: $0.93
Upside: +7,424.45%
Mar 16, 2022
Maintains: Buy
Price Target: $67 → $54
Current: $13.22
Upside: +308.47%
Mar 14, 2022
Downgrades: Underperform
Price Target: $270 → $90
Current: $36.81
Upside: +144.50%